Sensus Healthcare Q2 Revenue Misses by 50% as Unit Sales Fall
SRTS is trading near its 52-week low of $2.66 (2.3% above the low).
Summary
Sensus Healthcare reported Q2 revenue of $2.29 million, missing consensus estimates of $4.60 million by roughly 50%. The company posted a net loss of $8.75 million and an adjusted EBITDA loss of $3.02 million, wider than the expected $2.71 million loss. The revenue shortfall was driven by lower unit sales, including no sales to a historically large customer, and delayed recognition of eight units due to financing approval timing. Management expects to recognize revenue from those eight units in Q3 and highlighted a proposed 26% CMS reimbursement increase for hospital-based SRT delivery as a potential tailwind. This follows a 59% year-over-year revenue decline in Q1 and the recent replacement of its credit facility, underscoring ongoing liquidity and demand challenges. The stock trades near its 52-week low of $2.66, and the market will focus on whether the delayed units materialize in Q3 and whether the CMS proposal is finalized.
At the time of this announcement, SRTS was trading at $2.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52M. The 52-week trading range was $2.66 to $5.49. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.